Items Tagged ‘Recurrent Breast Cancer’

June 30th, 2016

Tecentriq™ Plus Abraxane® Effective Combo in Difficult to Treat Breast Cancer

By

The combination of the immune stimulating agent Tecentriq™ (atezolizumab), plus the chemotherapy agent Abraxane® (nab-paclitaxel) is effective in providing anti-cancer responses among patients with advanced triple-negative breast cancer (TNBC). These results were recently reported at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Approximately 10-20% of breast cancers are referred to […]

View full entry

Tags: Breast Cancer, immunotherapy, Metastatic Breast Cancer, News, Recurrent Breast Cancer, Tecentriq, tnbc, Triple Negative Breast Cancer


June 22nd, 2016

Directly Involving Patients Drives Participation in Metastatic Breast Cancer Study

By

A clinical study to accelerate research in metastatic breast cancer has rapidly enrolled participants through direct collaboration with patients. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). One large challenge in furthering research in the field of cancer is obtaining enough samples of tumor tissue […]

View full entry

Tags: Breast Cancer, clinical study, Metastatic Breast Cancer, News, Recurrent Breast Cancer


January 25th, 2016

ASCO Publishes Breast Cancer Survivorship Guidelines

By

The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated guidelines were recently published in the Journal of Clinical Oncology. There is an estimated 3.1 million breast cancer survivors alive today in the United States. At present, […]

View full entry

Tags: ACS, American cancer society, American Society of Clinical Oncology, Breast Cancer, Carcinoma In Situ Breast cancer, follow-up, guidelines, Inflammatory Breast Cancer, Metastatic Breast Cancer, News, Recurrent Breast Cancer, Screening/Prevention Breast Cancer


October 26th, 2015

Blood Test May Predict Cancer Recurrences Earlier than Standard Methods

By

A blood test that can detect circulating DNA from cancer cells appears to accurately predict the risk of a breast cancer recurrence 8 months earlier than standard detection methods among women with high-risk breast cancer. However, further study is necessary to confirm these findings and understand their benefit in a clinical setting. These results were […]

View full entry

Tags: blood test, Breast Cancer, ctDNA, detection, DNA, News, predict, Recurrent Breast Cancer, Screening/Prevention Breast Cancer


October 9th, 2015

Abemaciclib Receives FDA Breakthrough Therapy Designation in Advanced Breast Cancer

By

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to abemaciclib, a cyclin-dependent kinase (CDK) 4 and 6 inhibitor, for patients with refractory hormone-receptor-positive (HR+) advanced or metastatic breast cancer. According to the FDA, Breakthrough Therapy Designation is a process designed to expedite the development and review of drugs that are intended […]

View full entry

Tags: abemaciclib, Breast Cancer, CDK, hormone-receptor positive, HR+, metastatic, Metastatic Breast Cancer, MONARCH 3, News, Recurrent Breast Cancer


October 1st, 2015

Radiation Essential to Controlling Long-Term Recurrence in Women With Early Form of Breast Cancer

By

Doctors have reported that rates of breast cancer recurrences continue to increase, even after 12 years, among patients with ductal carcinoma in situ (DCIS) who do not receive radiation therapy as part of their treatment regimen. These results were recently published in the Journal of Clinical Oncology. DCIS is considered to be the earliest type […]

View full entry

Tags: Breast Cancer, Carcinoma In Situ Breast cancer, DCIS, News, radiation, recurrence, Recurrent Breast Cancer, study


August 4th, 2015

Role of Tumor Size and Estrogen-Receptor Status in Decline in Breast Cancer Deaths

By

In light of a general decline in breast cancer death since the late 1980s, research has now turned to how type and stage of disease affect survival among different women. These findings, which considered tumor size and estrogen-receptor (ER) status, were reported in the Journal of Clinical Oncology. The death rate from breast cancer overall has […]

View full entry

Tags: Breast Cancer, Metastatic Breast Cancer, News, Recurrent Breast Cancer, Stages II-III Breast Cancer


March 9th, 2015

Study Suggests Faslodex® Could Become New Standard First-Line Treatment of Metastatic Breast Cancer

By

Faslodex® (fulvestrant) at a 500-mg dose has been demonstrated to be superior to Arimidex® (anastrozole) as first-line therapy for advanced hormone receptor–positive breast cancer in the phase II FIRST study.1 Both overall survival and time to cancer progression were significantly better with Faslodex® than with the current standard of care, Arimidex®. Each year roughly 200,000 U.S. […]

View full entry

Tags: advanced hormone receptor-positive, anastrozole, Arimidex, Breast Cancer, CONFIRM, estrogen receptor antagonist, Faslodex, fulvestrant, Metastatic Breast Cancer, News, Recurrent Breast Cancer


March 5th, 2015

The Novel Small Molecule Pictilisib May Benefit Women with Advanced Breast Cancer

By

The addition of the investigational drug pictilisib to Faslodex® (fulvestrant) has been demonstrated to delay the time of cancer in women with advanced or metastatic breast cancer to be positive for both estrogen receptor (ER) and progesterone receptor (PR) who have previously failed treatment with an aromatase inhibitor. Each year roughly 200,000 U.S. women are […]

View full entry

Tags: Breast Cancer, Faslodex, fulvestrant, hormone-receptor positive, Metastatic Breast Cancer, News, pictilisib, Recurrent Breast Cancer


January 27th, 2015

Breast Cancer Research: Have We Made Progress?

By

Published results from research studies in breast cancer in the last year represent several practice changing milestones. CancerConnect News coverage of advances in the management of breast cancer included the following key developments: 2014: Have we Made Progress? Recent Study Finds That African American Women Less Likely To Receive Standard Breast Cancer Treatment Breast Cancer […]

View full entry

Tags: Breast Cancer, breast cancer research, Carcinoma In Situ Breast cancer, Inflammatory Breast Cancer, Metastatic Breast Cancer, News, Recurrent Breast Cancer, Screening/Prevention Breast Cancer, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer, Supportive Care Breast Cancer


December 18th, 2014

Breast Cancer Patients Are Now Living Longer without Relapse

By

Survival without relapse for patients with early-stage breast cancer has improved significantly over the past 30 years, particularly among women with HER2-positive disease. These findings were recently published in the Journal of Clinical Oncology. Cancer is considered relapsed when disease returns after it has been in remission following treatment, meaning that signs and symptoms have disappeared. Preventing relapse—or […]

View full entry

Tags: Breast Cancer, cancer, HER2, News, recurrence, Recurrent Breast Cancer, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer


December 15th, 2014

Neratinib Continues to Show Activity in HER2-Positive Breast Cancer

By

Interim results from an ongoing Phase II clinical trial of neratinib were presented at the 2014 San Antonio Breast Cancer Symposium (SABCS). Neratinib is an investigational, oral medication that targets HER2 as well as HER4 and the epidermal growth factor receptor (EGFR). Twenty to 25 percent of breast cancers overexpress (make too much of) a […]

View full entry

Tags: Breast Cancer, HER2, Metastatic Breast Cancer, neratinib, News, Recurrent Breast Cancer


December 10th, 2014

Initial Results of PD-1 Checkpoint Inhibitors Evaluated in Triple-Negative Breast Cancer Presented in San Antonio

By

The initial results from a phase 1 trial evaluating the checkpoint inhibitor Keytruda® (pembrolizumab) in patients with heavily pretreated triple-negative breast cancer were recently reported at the San Antonio Breast Cancer Symposium (SABCS). The cancer immunotherapy strategy known as programmed cell death 1 (PD-1) has generated great excitement for its ability to help the immune […]

View full entry

Tags: Breast Cancer, immunotherapy, keytruda, Metastatic Breast Cancer, News, PD-1, Recurrent Breast Cancer, tnbc, Triple Negative Breast Cancer


October 20th, 2014

Second-line Avastin Improves Progression-Free Survival in Advanced HER2-Negative Breast Cancer

By

Adding Avastin® (bevacizumab) to chemotherapy in second-line treatment of advanced HER2-negative breast cancer improves progression-free survival. Results of the phase III TANIA trial evaluating the role of Avastin® in advanced breast cancer were recently reported in The Lancet Oncology journalby von Minckwitz et al at The University Women’s Hospital, Frankfurt, Germany. The TANIA trial is […]

View full entry

Tags: avastin, bevacizumab, Breast Cancer, Metastatic Breast Cancer, News, Recurrent Breast Cancer


October 9th, 2014

Impressive Survival Gains with New First-Line Therapy for HER2-Positive Metastatic Breast Cancer

By

According to recent findings, the combination of targeted agents Herceptin® (trastuzumab) and Perjeta® (perjeta) significantly improves survival for patients with HER2-positive metastatic breast cancer when added to chemotherapy. This data was presented at the 2014 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, September 26–30.[1] HER2 is a protein involved in normal cell […]

View full entry

Tags: Breast Cancer, HER2, herceptin, Metastatic Breast Cancer, News, perjeta, Recurrent Breast Cancer